Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2010 1
2011 3
2012 3
2013 5
2014 7
2015 8
2016 9
2017 14
2018 17
2019 14
2020 16
2021 22
2022 14
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 29142926

113 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS; TEMPO 3:4 Trial Investigators. Torres VE, et al. Clin J Am Soc Nephrol. 2016 May 6;11(5):803-811. doi: 10.2215/CJN.06300615. Epub 2016 Feb 23. Clin J Am Soc Nephrol. 2016. PMID: 26912543 Free PMC article. Clinical Trial.
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS. Torres VE, et al. Am J Kidney Dis. 2011 May;57(5):692-9. doi: 10.1053/j.ajkd.2010.11.029. Epub 2011 Feb 17. Am J Kidney Dis. 2011. PMID: 21333426 Clinical Trial.
Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
Cornec-Le Gall E, Blais JD, Irazabal MV, Devuyst O, Gansevoort RT, Perrone RD, Chapman AB, Czerwiec FS, Ouyang J, Heyer CM, Senum SR, Le Meur Y, Torres VE, Harris PC. Cornec-Le Gall E, et al. Nephrol Dial Transplant. 2018 Apr 1;33(4):645-652. doi: 10.1093/ndt/gfx188. Nephrol Dial Transplant. 2018. PMID: 28992127 Free PMC article. Clinical Trial.
Overweight and Obesity and Progression of ADPKD.
Nowak KL, Steele C, Gitomer B, Wang W, Ouyang J, Chonchol MB. Nowak KL, et al. Clin J Am Soc Nephrol. 2021 Jun;16(6):908-915. doi: 10.2215/CJN.16871020. Epub 2021 Jun 11. Clin J Am Soc Nephrol. 2021. PMID: 34117082 Free PMC article.
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.
Gansevoort RT, Hariri A, Minini P, Ahn C, Chapman AB, Horie S, Knebelmann B, Mrug M, Ong ACM, Pei YPC, Torres VE, Modur V, Antonshchuk I, Perrone RD. Gansevoort RT, et al. Am J Kidney Dis. 2023 May;81(5):517-527.e1. doi: 10.1053/j.ajkd.2022.10.016. Epub 2022 Dec 17. Am J Kidney Dis. 2023. PMID: 36535535 Free article. Clinical Trial.
Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.
Gansevoort RT, Meijer E, Chapman AB, Czerwiec FS, Devuyst O, Grantham JJ, Higashihara E, Krasa HB, Ouyang J, Perrone RD, Torres VE; TEMPO 3:4 Investigators. Gansevoort RT, et al. Nephrol Dial Transplant. 2016 Nov;31(11):1887-1894. doi: 10.1093/ndt/gfv422. Epub 2015 Dec 17. Nephrol Dial Transplant. 2016. PMID: 26681730 Free PMC article. Clinical Trial.
113 results